<DOC>
	<DOCNO>NCT00959101</DOCNO>
	<brief_summary>This trial conduct Asia . The aim clinical trial investigate bioequivalence repaglinide metformin combination tablet versus repaglinide metformin coadministered tablet meal . The trial design three-period , six-sequence , single-dose , crossover pharmacokinetic trial trial participant randomise one six possible treatment period ( Williams design ) . The trial participant receive one single dose trial product vary order .</brief_summary>
	<brief_title>Comparison Repaglinide Metformin Combination Tablet Versus Repaglinide Metformin Separate Tablets Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Willing sign inform consent initiate trial related procedure BMI : 19.025.0 kg/m2 Fasting plasma glucose : 3.96.1 mmol/L Trial participant judge good health basis medical history , physical examination , ECG , routine laboratory data Any clinically significant disease history , opinion Investigator , systemic organ disease Clinically significant abnormality prestudy clinical examination laboratory measurement screen Any regular use prescription nonprescription drug , include megavitamin herbal supplement regimen stop least two week prior start treatment duration trial Currently smoker ( one cigarette per day equivalent ) Use grapefruit grapefruit juice within 7 day trial product dose administration Blood donation , surgery trauma significant blood loss ( 400 mL ) within last 2 month prior trial product dose administration Recent history ( within last 2 year ) drug alcohol abuse Known suspect allergy trial product excipients history multiple and/or severe allergy drug food severe anaphylactic reaction Subject take investigational drug another clinical trial within last 4 week . Recent history ( within last 3 month ) nausea , diarrhea gastrointestinal complaint History illness , opinion Investigator , might confound result trial pose additional risk administer trial product trial participant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>